Medicinal cannabis company Zelda Therapeutics (ASX:ZLD) has announced that its clinical trial for insomnia is now fully enrolled.
The trial is being led by the University of Western Australia (UWA) Centre for Sleep Science (CSS) and is evaluating the safety and efficacy of a cannabinoid extract containing THC and CBD in patients with symptoms of clinically diagnosed chronic insomnia.
The primary endpoint of the trial is to assess the impact of a full-spectrum cannabis extract on sleep.
Dr Richard Hopkins, Zelda’s managing director, said “This is an important milestone for the trial. I acknowledge the hard work and dedication from the team at the UWA sleep centre.
"Should the trial be successful, the Company will move to immediately commercialise this formulation in all major global medicinal cannabis markets.
"Zelda’s proposed merger with US-based Ilera Therapeutics will expand our access to the world’s largest cannabis markets with approximately four million registered medicinal cannabis patients. Zelda’s strategic partnership with European medicinal cannabis group HAPA Pharm BV also helps us access the world’s fastest growing markets outside the US.”
The company added that dosing is on-track for completion by December 2019 with preliminary results expected by February 2020.